Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Pilot trial of secukinumab in active non-segmental vitiligo
2015-003552-48Phase 4Completed
- Sponsor
- Ghent University Hospital
- Start
- Feb 2016
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, single-arm trial of secukinumab in Vitiligo, sponsored by Ghent University Hospital. Primary endpoint: Primary efficacy of secukinumab in active vitiligo. Started Feb 2016; status: completed.
02
Drugs
secukinumab
03
Conditions
Vitiligo
Beyond the preview
Go deeper on 2015-003552-48.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2015-003552-48.